$110.00
2.02% day before yesterday
Nasdaq, Dec 26, 10:00 pm CET
ISIN
US76243J1051
Symbol
RYTM

Rhythm Pharmaceuticals, Inc. Stock price

$110.00
+2.58 2.40% 1M
+48.56 79.02% 6M
+54.02 96.50% YTD
+53.46 94.55% 1Y
+80.76 276.20% 3Y
+80.59 274.02% 5Y
+80.00 266.67% 10Y
+80.00 266.67% 20Y
Nasdaq, Closing price Fri, Dec 26 2025
-2.27 2.02%
ISIN
US76243J1051
Symbol
RYTM
Industry

Key metrics

Basic
Market capitalization
$7.3b
Enterprise Value
$7.0b
Net debt
positive
Cash
$416.1m
Shares outstanding
66.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
42.1 | 38.3
EV/Sales
40.4 | 36.7
EV/FCF
negative
P/B
24.8
Financial Health
Equity Ratio
42.0%
Return on Equity
-160.8%
ROCE
-46.3%
ROIC
-412.7%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$174.3m | $191.7m
EBITDA
$-184.8m | $-194.4m
EBIT
$-186.2m | $-199.6m
Net Income
$-197.7m | $-217.7m
Free Cash Flow
$-109.1m
Growth (TTM | estimate)
Revenue
25.9% | 47.3%
EBITDA
54.2% | 26.4%
EBIT
54.1% | 24.8%
Net Income
50.9% | 17.7%
Free Cash Flow
12.3%
Margin (TTM | estimate)
Gross
89.4%
EBITDA
-106.0% | -101.4%
EBIT
-106.8%
Net
-113.4% | -113.6%
Free Cash Flow
-62.6%
More
EPS
$-3.0
FCF per Share
$-1.6
Short interest
10.7%
Employees
283
Rev per Employee
$460.0k
Show more

Is Rhythm Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Rhythm Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

19x Buy
90%
2x Hold
10%

Analyst Opinions

21 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

Buy
90%
Hold
10%

Financial data from Rhythm Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
174 174
26% 26%
100%
- Direct Costs 18 18
18% 18%
11%
156 156
27% 27%
89%
- Selling and Administrative Expenses 176 176
2% 2%
101%
- Research and Development Expense 166 166
53% 53%
95%
-185 -185
54% 54%
-106%
- Depreciation and Amortization 1.45 1.45
9% 9%
1%
EBIT (Operating Income) EBIT -186 -186
54% 54%
-107%
Net Profit -198 -198
51% 51%
-113%

In millions USD.

Don't miss a Thing! We will send you all news about Rhythm Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rhythm Pharmaceuticals, Inc. Stock News

Positive
Seeking Alpha
16 days ago
Rhythm Pharmaceuticals, Inc. remains a compelling rare-disease obesity platform, with a maintained Buy rating driven by progress in HO, PWS, and oral MC4R agonists. PWS Phase 2 data for IMCIVREE show early efficacy in BMI and hyperphagia reduction, though limited by small sample size and responder heterogeneity. RYTM's HO sNDA PDUFA was delayed to March 2026 for additional FDA analysis, but I r...
Neutral
Seeking Alpha
16 days ago
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript
Positive
Investors Business Daily
16 days ago
Rhythm Pharmaceuticals said Thursday said it would send it would send its leading drug into registrational testing for Prader-Willi.
More Rhythm Pharmaceuticals, Inc. News

Company Profile

Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Head office United States
CEO David Meeker
Employees 283
Founded 2008
Website rhythmtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today